Unicycive Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNCY research report →
Companywww.unicycive.com
Unicycive Therapeutics, Inc. , a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.
- CEO
- Shalabh K. Gupta
- IPO
- 2021
- Employees
- 22
- HQ
- Los Altos, CA, US
Price Chart
Valuation
- Market Cap
- $166.34M
- P/E
- -46.32
- P/S
- 0.00
- P/B
- 49.08
- EV/EBITDA
- -3.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.18%
- ROIC
- -77.80%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,555,000 · 27.70%
- EPS
- $-1.67 · 70.18%
- Op Income
- $-29,517,000
- FCF YoY
- -9.40%
Performance & Tape
- 52W High
- $11.00
- 52W Low
- $3.71
- 50D MA
- $7.21
- 200D MA
- $5.83
- Beta
- 1.77
- Avg Volume
- 534.34K
Get TickerSpark's AI analysis on UNCY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Jermasek Douglas | other | 169,500 |
| May 14, 26 | Gupta Pramod | other | 169,500 |
| May 14, 26 | Townsend John | other | 169,500 |
| May 14, 26 | Laumas Sandeep | other | 42,100 |
| May 14, 26 | Laumas Sandeep | other | 84,200 |
| Aug 25, 25 | Aggarwal Gaurav | other | 652,900 |
| Aug 25, 25 | Aggarwal Gaurav | sell | 3,199.21 |
| Jul 28, 25 | Aggarwal Gaurav | other | 21,200 |
| Jul 28, 25 | Laumas Sandeep | other | 21,200 |
| Jul 28, 25 | Kenkare-Mitra Sara | other | 21,200 |
Our UNCY Coverage
We haven't published any research on UNCY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UNCY Report →